The development of specialized AI chips is currently revolutionizing laboratory medicine and opening up new possibilities for faster and more precise diagnostics. These chips, also known as neuromorphic processors or AI accelerators, are optimized for executing machine learning algorithms and processing large amounts of data. A leading provider in this field is NVIDIA with its DGX platform. The NVIDIA A100 Tensor Core GPU, the core of this platform, can deliver up to 624 teraflops of AI computing power[2]. This enables a drastic acceleration of AI applications in laboratory diagnostics, such as in the analysis of medical imaging procedures or genome sequencing. Intel has developed a compact solution for edge computing in laboratories with its Movidius Neural Compute Stick 2. This USB stick-shaped AI accelerator offers computing power of up to 4 teraflops with a power consumption of only 1 watt, making it ideal for use in portable diagnostic devices[2]. Google’s Tensor Processing Unit (TPU)… 

The pharmaceutical industry is witnessing a paradigm shift as artificial intelligence (AI) transforms the landscape of drug development. Traditionally a lengthy and costly process, the creation of new medications is now being accelerated and streamlined through the application of AI technologies. A recent whitepaper by the Learning Systems Platform highlights that AI implementation can significantly reduce the time from initial concept to drug approval. Currently, it takes an average of twelve years for a new drug to reach the market, with costs around $2.8 billion. AI-driven methods promise to substantially cut both time and expenses. Concrete successes are already emerging. Biotech company Amgen has managed to shorten the development time for protein drug candidates to clinical trials by 60 percent. This was achieved through the use of AI-based computer models in combination with automated high-throughput laboratory procedures. One promising area… 

The Gebührenordnung für Ärzte (GOÄ) is an important legal basis for the billing of medical services outside the statutory health insurance system in Germany[1][3]. It is issued as a legal ordinance by the Federal Government with the approval of the Bundesrat and regulates the remuneration for private medical services[1][4]. The GOÄ has a long history dating back to the 19th century. Its current form dates back to 1982, with the last partial amendment in 1996[2][4]. The GOÄ lists all medical services with corresponding fee numbers and point values[3]. The remuneration for a service is calculated by multiplying the point value by an increase factor, which can range from one to 3.5 times the base value[3]. The doctor determines the increase factor based on the difficulty and time required for the treatment, with the 2.3x rate considered average[3]. Exceeding the 2.3x rate must be justified[3]. The GOÄ is divided into different sections, which cover different…